Tofacitinib (CP-690550)

For research use only.

Licensed by Pfizer Catalog No.S2789 Synonyms: Tasocitinib

122 publications

Tofacitinib (CP-690550) Chemical Structure

CAS No. 477600-75-2

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.

Selleck's Tofacitinib (CP-690550) has been cited by 122 publications

Purity & Quality Control

Choose Selective JAK Inhibitors

Biological Activity

Description Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.
Targets
JAK3 [1]
(Cell-free assay)
JAK2 [1]
(Cell-free assay)
JAK1 [1]
(Cell-free assay)
1 nM 20 nM 112 nM
In vitro

CP-690550 is a specific, orally inhibitor of JAK3, it is 20- to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2–induced proliferation with 30-fold greater potency than its effects on GM-CSF–induced proliferation. [1] CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM). [2] CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells. [3] A recent research indicates low dose of CP-690550 accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T cells NHW4XZFHfW6ldHnvckBCe3OjeR?= NEnacY8xNjFxMD6zM|Eh|ryP M2XwTlI1KGh? NHLtbFRlcXO{dYD0d{DPu2NvY3jhbY4h[3m2b3vpcoUhe2mpbnHsbY5o MmHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEOyOFEoRjJzM{izNlQyRC:jPh?=
CD4+ T  MmnBSpVv[3Srb36gRZN{[Xl? MUOxNFAhdk1? MmjrNlQwPDhiaB?= M4i3OYFjem:pYYTld{BETDNvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiU2TBWJM> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6NEW4NEc,OjF6OES1PFA9N2F-
CD4+ T  NE\vb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml25NVAxNzVyMDDuUS=> M{jOUFQ5KGh? MVXpcohq[mm2czDhcpRqNUOGMz3pcoR2[2WmIFPEOEvDqFRiY3XscEBxem:uaX\ldoF1cW:w MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6NEW4NEc,OjF6OES1PFA9N2F-
CD4+ T  NYDk[oI4TnWwY4Tpc44hSXO|YYm= NEDNTmQzOC9zMECvOVAxKG6P NGXOPWY1QCCq MnfUbY5pcWKrdIOgeIhmKGyndnXsd{Bw\iBiSVytOEwhUU[QLd8zMEBKVC1zN1GgZY5lKEmOLUKy NHXl[IY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi4OFU5OCd-MkG4PFQ2QDB:L3G+
Sf9 MmfjSpVv[3Srb36gZZN{[Xl? MlLxN|AhdWmwcx?= NGrLO4tKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD3meZNm\CCMQVuzJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|LXnu[oVkfGWmIGPmPUBk\WyuczD1d4lv\yCyb3z5[4x2fGGvaXOgZYNq\C22eYLvd4lv\SCjczDzeYJ{fHKjdHWgZYZ1\XJiM{CgcYlveyCkeTDFUGlUSSxiS3mgQUAxNjByMESg{txONg>? NHLqPJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2PFQ5PCd-MkO2Olg1QDR:L3G+
Sf9 NIjkfYZHfW6ldHnvckBie3OjeR?= MYC5NEBucW6| M3G4[GlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiTj30[ZJucW6jbDDHV3QufGGpZ3XkJGpCUzNiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{B2e2mwZzDCbY91cW5vTFOtSXFGTEWSRVfEXWZGX0yHIHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHRTNU[URWSgZZN{[XluIFnDOVAhRSByLkCwNFYh|ryPLh?= NX24ZXkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
Sf9 NILIcWNHfW6ldHnvckBie3OjeR?= M2PYSFMxKG2rboO= MkTzTY5pcWKrdHnvckBw\iCqdX3hckBIW1RvZoXz[YQhUkGNMTDjZZRidHm2aXOg[I9u[WmwIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcocheG:ueXfseZRidWmlIHHjbYQufHm{b4PpcoUh[XNic4Xid5Rz[XSnIHHmeIVzKDNyIH3pcpMh[nliRVzJV2EtKEurIE2gNE4xODB5IN88UU4> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4OES4OEc,OjN4Nki0PFQ9N2F-
Sf9 MV;GeY5kfGmxbjDhd5NigQ>? NVLsfoJ3OzBibXnudy=> NEXybJpKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD3meZNm\CCMQVuyJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|LXnu[oVkfGWmIGPmPUBk\WyuczD1d4lv\yCyb3z5[4x2fGGvaXOgZYNq\C22eYLvd4lv\SCjczDzeYJ{fHKjdHWgZYZ1\XJiM{CgcYlveyCkeTDFUGlUSSxiS3mgQUAxNjByMEeg{txONg>? NFzNN2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2PFQ5PCd-MkO2Olg1QDR:L3G+
Sf9 M{LnbGZ2dmO2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEeVVD30ZYdo\WRiSlixJIRwdWGrbjCoO|g2KHSxMUGyOUkhd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoOTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMECxJO69VS5? NWH5RWR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
Sf9 MmDNSpVv[3Srb36gZZN{[Xl? M2DQNWlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDoeY1idiCMQVuzJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMECxJO69VS5? NIXL[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOVcyOSd-MkGxNFU4OTF:L3G+
Sf9 NF3VVYpHfW6ldHnvckBie3OjeR?= MkXUPVAhdWmwcx?= M3LybWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiTj30[ZJucW6jbDDHV3QufGGpZ3XkJGpCUzFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{B2e2mwZzDCbY91cW5vTFOtSXFGTEWSRVfEXWZGX0yHIHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHRTNU[URWSgZZN{[XluIFnDOVAhRSByLkCwN{DPxE1w NXvM[Hd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
Sf9 M1y3e2Z2dmO2aX;uJIF{e2G7 M3fhNmlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDoeY1idiCMQVuzJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMECzN{DPxE1w MljYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMEW3NVEoRjJzMUC1O|EyRC:jPh?=
Sf9 MYrGeY5kfGmxbjDhd5NigQ>? NIHrOoY6OCCvaX7z NHS2dG5KdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IF6teIVzdWmwYXygS3NVNXSjZ3fl[EBLSUt{IHX4dJJme3OnZDDpckBU\jliY3XscJMhfXOrbnegRolwfGmwLVzDMWVSTUSHUFXHSHlHTVeORTDhd{B{fWK|dILheIUh[W[2ZYKgPVAhdWmwczDifUBVWi2IUlXUJIF{e2G7LDDJR|UxKD1iMD6wNFQh|ryPLh?= M{LCXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
SF21 MU\GeY5kfGmxbjDhd5NigQ>? NWntUmY5OTBibXnudy=> MnqwTY5pcWKrdHnvckBw\iCMQVuyJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKFOIMkGgZ4VtdHNidYPpcochSmmxdHnuMWtCUUWWRFvFXXlVXkuGIHHzJJN2[nO2cnH0[UBidmRiW{OzVIdidW2jXVHUVEBqdmO3YnH0[YQh\m:{IEGwJI1qdnNicILpc5IhfG9ic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliVH;wZ492dnRiYX7hcJl{cXNuIFnDOVAhRSByLkCwOEDPxE1w MnPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEG2O|AoRjJ|NUSxOlcxRC:jPh?=
insect cells Mny3SpVv[3Srb36gZZN{[Xl? MoD0TY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIFrhb|Eh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{B2e2mwZzC3NEB2VSCDVGCsJGlEPTBiPTCwMlAxPjFizszNMi=> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NU[wOUc,OjFzNUW2NFU9N2F-
insect cells M4C3OWZ2dmO2aX;uJIF{e2G7 NUnteG1NUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJGpiczNiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyC3c3nu[{AyQCC3TTDBWHAtKEmFNUCgQUAxNjByODFOwG0v NYe3VpR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOVU3ODVpPkKxNVU2PjB3PD;hQi=>
T-cells M4j1TGZ2dmO2aX;uJIF{e2G7 NFjsd4o4OiCqcoO= NHPhdJhKdmirYnn0bY9vKG:oIFnMNk1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iVDDj[YxteyCjc4Pld5Nm\CCjczDbN2hefGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjBzMTFOwG0v M4jPZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
insect cells NFnje5FHfW6ldHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiSnHrNkBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIEKwJJVOKEGWUDygTWM2OCB;IECuNFEzKM7:TT6= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NU[wOUc,OjFzNUW2NFU9N2F-
MO7 MoDMSpVv[3Srb36gZZN{[Xl? MYrJcohq[mm2aX;uJI9nKEqja{OtcYVlcWG2ZXSgTWwyPS2rbnT1Z4VlKFO2YYS1JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNU|ch[2WubIOgZpkh[2WubD3iZZNm\CCjc4PhfUwhUUN3MDC9JFAvODJ2IN88UU4> M4m1RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OlA2Lz5{MUG1OVYxPTxxYU6=
Ba/F3 Mo\aSpVv[3Srb36gZZN{[Xl? NFLMPWU3OCCvaX7z MVrJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCMQVuxJIV5eHKnc4Pl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBi\nSncjC2NEBucW6|IHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNE4xOjZizszNMi=> MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
T-cells NETwR4xHfW6ldHnvckBie3OjeR?= M4LJUmlvcGmkaYTpc44hd2ZiSlHLN{8yKGmwIHj1cYFvKFRiY3XscJMh\XiycnXzd4lv\yCFREOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDJUFIue3SrbYXsZZRm\CCVVFHUOYEheGixc4Doc5J6dGG2aX;uMEBKSzVyIE2gNE4xOjhizszNMi=> NUHZNJJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDhpPkKzOVQxPjR6PD;hQi=>
PBMC NXHUbnZUTnWwY4Tpc44h[XO|YYm= M1rUNWlvcGmkaYTpc44hUUxvNz3pcoRkfWWmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSk2FIHPlcIx{KGK7IH\sc5ch[3m2b33leJJ6NCCLQ{WwJF0hOC5yM{mg{txONg>? NInvdZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmyO|QzOyd-Mk[5Nlc1OjN:L3G+
TF1 NUToeHVNTnWwY4Tpc44h[XO|YYm= M{DkUFIxKG2rboO= NXP1UGE4UW6qaXLpeIlwdiCxZjDKRWsyKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmONj3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgTWw3KGOqYXzs[Y5o\SCob4KgN|AhdWmwczDpckBxemW|ZX7j[UBw\iC5aH;s[UBjdG:xZDygSWM2OCB;IECuNFQ{KM7:TT6= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3OUKxOEc,OjN4NUmyNVQ9N2F-
TF1 MnXLSpVv[3Srb36gZZN{[Xl? NYL5[HJHUW6qaXLpeIlwdiCxZjDKRWsyKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCLTE[td5RqdXWuYYTl[EBUXEGWMzDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO|YYmsJGlPUCB;IECuNFQ2KM7:TT6= NUTaelM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO|I3PTNpPkK2N|czPjV|PD;hQi=>
CTLL M2DmdWZ2dmO2aX;uJIF{e2G7 NITsSnlKdmirYnn0bY9vKG:oIFrhb|MudWWmaXH0[YQhUUx{LXnu[JVk\WRiU4TheFUheGixc4Doc5J6dGG2aX;uJIlvKG2xdYPlJGNVVExiY3XscJMh[nliY3XscE1j[XOnZDDhd5NigSxiSVO1NEA:KDBwMES4JO69VS5? NVrFZpFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOVU3ODVpPkKxNVU2PjB3PD;hQi=>
Sf9 MVPGeY5kfGmxbjDhd5NigQ>? NHe1fYs6OCCvaX7z MkTlTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgWHlMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJJV{cW6pIFLpc5Rqdi2OQz3FVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDBwMEWyJO69VS5? MlXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
TF1 M2LmZWZ2dmO2aX;uJIF{e2G7 NInabmhKdmirYnn0bY9vKG:oIFrBT|EhcW5iaIXtZY4hXEZzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUUx{LXnu[JVk\WRiU2TBWFMheGixc4Doc5J6dGG2aX;uMEBGSzVyIE2gNE4xPTNizszNMi=> M1v6elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUmxOFAzLz5{MkW5NVQxOjxxYU6=
TF1 MW\GeY5kfGmxbjDhd5NigQ>? NWn2eYdROjBibXnudy=> M4LKUGlvcGmkaYTpc44hd2ZiSlHLNUBqdiCqdX3hckBVTjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVDZvaX7keYNm\CCVVFHUN{BxcG:|cHjvdplt[XSrb36gbY5kfWKjdHXkJIZweiB{MDDtbY5{KHC{aX;yJJRwKEmONj3pcoR2[3Srb36gcYVie3W{ZXSgZYZ1\XJiM{CgeI8hPDVibXnud{whTUN3MDC9JFAvODV|IN88UU4> NXLiW5ZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PVgxQDRpPkKyOlk5ODh2PD;hQi=>
TF1 MVLGeY5kfGmxbjDhd5NigQ>? M3\KeFIxKG2rboO= Ml7mTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNPi2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMh\m:ubH;3[YQh[nliSVy2JINp[WyuZX7n[UBnd3JiM{CgcYlveyxiRVO1NEA:KDBwMEWzJO69VS5? NE[3VnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[1PVIyPCd-MkO2OVkzOTR:L3G+
Ba/F3 MYrGeY5kfGmxbjDhd5NigQ>? MV:2NEBucW6| NUn0OYl2UW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgTmFMOyCneIDy[ZN{\WRiaX6gRoEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25iYX\0[ZIhPjBibXnud{BjgSCDbIDoZXNkemWnbjDhd5NigSxiSVO1NEA:KDBwMEW0JO69VS5? Mn;IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
T-cells M4q1emZ2dmO2aX;uJIF{e2G7 Mnj5TY5pcWKrdHnvckBw\iCjbHzv[4VvcWNiY3XscJMue3SrbYXsZZRm\CCycn;sbYZmemG2aX;uJIlvKG2xbnvlfUBVKGOnbHzzJIJ6KG2reHXkJIx6dXCqb3P5eIUhemWjY4Tpc44hdWW2aH;kMEBKSzVyIE2gNE4xPTdizszNMi=> MofFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
CD34+ NXf4R5lmTnWwY4Tpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gR2Q{PCtiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBGWE9vbXXkbYF1\WRiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxKD1iMD6wO|Eh|ryPLh?= NYHKe2V{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5Nlc1OjNpPkK2PVI4PDJ|PD;hQi=>
TF1 M2Pkc2Z2dmO2aX;uJIF{e2G7 MkLDTY5pcWKrdHnvckBw\iCLTEStbY5lfWOnZDDwdo9tcW[ncnH0bY9vKG:oIGTGNUBk\WyuczygTWM2OCB;IECuNFgh|ryPLh?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl|NES1O{c,OTZ7M{S0OVc9N2F-
T-cells MXHGeY5kfGmxbjDhd5NigQ>? NF\jd|JKdmirYnn0bY9vKG:oIHHscI9o\W6rYzDj[Yxtey2|dHnteYxifGWmIIDyc4xq\mW{YYTpc44hcW5iaIXtZY4hXCClZXzsd{BjgSCvaYjl[EBtgW2yaH;jfZRmKHKnYXP0bY9vKG2ndHjv[EwhUUN3MDC9JFAvODh5IN88UU4> MmToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
TF1 NX7wT|hETnWwY4Tpc44h[XO|YYm= NEL2TWwzOCCvaX7z NHfHcYZKdmirYnn0bY9vKG:oIFrBT|IhcW5iaIXtZY4hXEZzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTVCRLXnu[JVk\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIlv[3WkYYTl[EBnd3JiMkCgcYlveyCycnnvdkB1dyCHUF:tbY5lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJJRwKDR3IH3pcpMtKEWFNUCgQUAxNjB7MzFOwG0v M{XTRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nkm4NFg1Lz5{Mk[5PFA5PDxxYU6=
TF1 MXPGeY5kfGmxbjDhd5NigQ>? MX[yNEBucW6| MU\Jcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSXBQNWmwZIXj[YQhW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhOjBibXnud{Bnd2yub4fl[EBjgSCLTE[gZ4hidGynbnflJIZweiB|MDDtbY5{NCCHQ{WwJF0hOC5yOUOg{txONg>? NH3kVos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[1PVIyPCd-MkO2OVkzOTR:L3G+
PBMC MWLGeY5kfGmxbjDhd5NigQ>? MVXJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gVGJOSyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNNTZvaX7keYNm\CCPQ2CxJJNm[3KndHnvckwhUUN3MDC9JFAvODl3IN88UU4> Mn\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7Mke0NlMoRjJ4OUK3OFI{RC:jPh?=
TF1 NULwZ2xYTnWwY4Tpc44h[XO|YYm= MmPCNkBpenN? MkDFTY5pcWKrdHnvckBw\iCMQVuyJIlvKEePQ2PGMZN1cW23bHH0[YQhcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHNVSVR3IIDoc5NxcG:{eXzheIlwdiCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEePQ2PGJJN1cW23bHH0bY9vKG[xcjC1NEBucW6|IHL5JGZCS1NicnXh[IVzKGGwYXz5d4l{NCCLQ{WwJF0hOC5yOUWg{txONg>? MkTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{CzOVkoRjJ5MUOwN|U6RC:jPh?=
TF1 NEe1[45HfW6ldHnvckBie3OjeR?= NEjQbGFKdmirYnn0bY9vKG:oIFrBT|IhcW5iRWDPMZN1cW23bHH0[YQhcHWvYX6gWGYyKGOnbHzzJIV5eHKnc4Ppcoche3SjYnz5JIlvfGWpcnH0[YQh[mW2YT3sZYN1[W2jc3WgdoVxd3K2ZYKg[4Vv\SC3bnTldkBkd262cn;sJI9nKFOWQWS1JJJme3CxboPlJIVt\W2nboTzJIlvKGmwdHXy[oVzd25icnXneYxifG:{eTDmZYN1d3JiMTDn[Y5mKHC{b33veIVzKGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNVA4KM7:TT6= NGr3SVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1OlE{Pid-MkmxOVYyOzZ:L3G+
Sf9 MoHTSpVv[3Srb36gZZN{[Xl? M4DRS2lvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDoeY1idiCMQVuxJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMUGg{txONg>? MmrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMEW3NVEoRjJzMUC1O|EyRC:jPh?=
T-cells M1fUZ2Z2dmO2aX;uJIF{e2G7 NXfEfYVOUW6qaXLpeIlwdiCxZjDhcIxw\2WwaXOgZ4VtdHNvc4TpcZVt[XSnZDDwdo9tcW[ncnH0bY9vKGmwIH3veZNmKFRiY3XscJMh[nlibXn4[YQhdHmvcHjvZ5l1\SC{ZXHjeIlwdiCvZYToc4QtKEmFNUCgQUAxNjFzNTFOwG0v NV73[XZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
ME180 NFLSb5RHfW6ldHnvckBie3OjeR?= NGP4boZKdmirYnn0bY9vKG:oIFrBT|EhcW5iSVy2MZN1cW23bHH0[YQhcHWvYX6gUWUyQDBiY3XscJMh\XiycnXzd4lv\yC|dHHicJkhcW62ZXfyZZRm\CCkZYThMYxi[3SjbXHz[UBz\XCxcoTldkBo\W6nIIXu[IVzKGOxboTyc4whd2Zic3nzMYlv\HWlaXLs[UBmdGWvZX70JIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMUK0JO69VS5? NYLYUXhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOVYyOzZpPkK5NVU3OTN4PD;hQi=>
CTLL-2 MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NUnJeplVPzJiaILz NVKybWJUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBKVC1{LYP0bY12dGG2ZXSgcY92e2ViQ2TMUE0zKGOnbHzzJIV5eHKnc4PpcochUkGNMT;KRWs{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvOTN{IN88UU4> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzPEc,OTl5NkKyN|g9N2F-
HT2 MWnGeY5kfGmxbjDhd5NigQ>? MWPJcohq[mm2aX;uJI9nKEqDS{OgbY4hdW:3c3WgTHQzKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINmdGxiZ4Lve5RpNCCLQ{WwJF0hOC5zNU[g{txONg>? NXG0XVVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|EyQDBpPkK3O|cyOThyPD;hQi=>
DND/L12 M{np[GZ2dmO2aX;uJIF{e2G7 NH;pUpc{OCCvaX7z M1jmN2lvcGmkaYTpc44hd2ZiSlHLN{BqdiCqdX3hckBFVkRxTEGyJINmdGy|IHHmeIVzKDNyIH3pcpMh[nlibIXjbYZmemG|ZTDhd5NigSCrbjDwdoV{\W6lZTDv[kBpfW2jbjDz[ZJ2dSCjbHL1cYlvNCCLQ{mwJF0hOC5zNjFOwG0v MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
T-cells NWfXc5Y4TnWwY4Tpc44h[XO|YYm= M4f4VWlvcGmkaYTpc44hd2ZiSlHLNk8yKGmwIHj1cYFvKFRiY3XscJMh\XiycnXzd4lv\yCFREOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDJSm5o[W2vYT3zeIlufWyjdHXkJHNVSVRzIIDoc5NxcG:{eXzheIlwdixiSVO1NEA:KDBwMUeg{txONg>? NF;ESWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0NFY1QCd-MkO1OFA3PDh:L3G+
insect NGK3eXFHfW6ldHnvckBie3OjeR?= MVnJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiVInrNkBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIEO1JJVOKEGWUDygTWM2OCB;IECuNVc3KM7:TT6= M3zGWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OlA2Lz5{MUG1OVYxPTxxYU6=
Ba/F3 MVPGeY5kfGmxbjDhd5NigQ>? NVvPb2x7PjBibXnudy=> NYDB[mJxUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgTmFMOiCneIDy[ZN{\WRiaX6gRoEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25iYX\0[ZIhPjBibXnud{BjgSCDbIDoZXNkemWnbjDhd5NigSxiSVO1NEA:KDBwMk[1JO69VS5? NEfxWYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC4O|c2OCd-MkKwPFc4PTB:L3G+
TF1 MX;GeY5kfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINmdGxiZ4Lve5RpNCCLQ{WwJF0hOC5{N{WxJO69VS5? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5MUG4NEc,Ojd5N{GxPFA9N2F-
CD34+ Ml\oSpVv[3Srb36gZZN{[Xl? NFnBV5JKdmirYnn0bY9vKG:oIFrBT|IhcG:vb3TpcYVzKGmwIHj1cYFvKEOGM{SrJINmdGy|IIPwbYtm\CCrboTvJIh2dWGwIIfoc4xmKGKub3;kJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSXBQNWmwZIXj[YQhW1SDVD21JJBpd3OyaH;yfYxifGmxbjDwdoVqdmO3YnH0[YQh\m:{IES1JI1qdnNiZn;scI94\WRiYomgSXBQKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFE2KG2rboOgZpkhTkGFUzDhcoFtgXOrczygTWM2OCB;IECuN|AzKM7:TT6= MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1N|MoRjJ2NEG3OVM{RC:jPh?=
HUO3 M1P4emZ2dmO2aX;uJIF{e2G7 M3;rT|Qh\GG7cx?= M1jpUWlvcGmkaYTpc44hd2ZiaIXtZY4hT01vQ2PGMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCrbjDoeY1idiCKVV:zJINmdGy|IHHzd4V{e2WmIHHzJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC0JIRigXNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwM{K0JO69VS5? M3vBfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
HU03 NFqwVIVHfW6ldHnvckBie3OjeR?= MUW3NkBpenN? NVvRZ|gxUW6qaXLpeIlwdiCxZjDHUU1EW0ZvaX7keYNm\CCqdX3hckBJXTB|IHPlcIx{KHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGuzTH11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwM{K0JO69VS5? NGfxNHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOVcyOSd-MkGxNFU4OTF:L3G+
BAF3 NH;HcndCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MkfnO|IhcHK| MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiZYjwdoV{e2mwZzDUSWwuUkGNMzDrbY5ie2ViYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC53NzFOwG0v MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NkKyN|goRjF7N{[yNlM5RC:jPh?=
T-cells NHTMfHhHfW6ldHnvckBie3OjeR?= MYezJIRigXN? MVrJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxZjDJUFIu[WO2aY\heIVlKGGwZDDDSFMh[W6mIFPENlgh[W62aXLv[Jkue3SrbYXsZZRm\CCvb4Xz[UBETDRvcH;zbZRqfmViVDDj[YxteyCjZoTldkA{KGSjeYOgZpkhYFSWIHHzd4F6NCCLQ{WwJF0hOC54MzFOwG0v MknBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2NkC4OFIoRjNyNE[wPFQzRC:jPh?=
NK92 MVjGeY5kfGmxbjDhd5NigQ>? M4HVd|IxKG2rboO= NEnVbXBKdmirYnn0bY9vKG:oIGTZT|IhcW5iaIXtZY4hVkt7MjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmOMUKtbY5lfWOnZDDTWGFVPCCyaH;zdIhwenmuYYTpc44hcW6ldXLheIVlKG[xcjCyNEBucW6|IH\vcIxwf2WmIHL5JGlNOTJiY3jhcIxmdmenIH\vdkA1PSCvaX7zMEBGSzVyIE2gNE44OSEQvF2u M{izT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkW5NlE1Lz5{M{[1PVIyPDxxYU6=
TF1 NXvk[IxETnWwY4Tpc44h[XO|YYm= NUHWb5VqUW6qaXLpeIlwdiCxZjDJUFMucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJHRHOSClZXzsd{whUUN3MDC9JFAvQCEQvF2u MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl|NES1O{c,OTZ7M{S0OVc9N2F-
UT7 M1TJS2Z2dmO2aX;uJIF{e2G7 MlWwTY5pcWKrdHnvckBw\iCMQVuyJIlvKGi3bXHuJHVVPyClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBGWE9vc4TpcZVt[XSnZDDTWGFVPSCyaH;zdIhwenmuYYTpc44h[nliQXzwbIFU[3KnZX6gZZN{[XluIFnOTEA:KDFwMUKg{txONg>? NX;TfoNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO|I3PTNpPkK2N|czPjV|PD;hQi=>
Ba/F3 NXXNcItOTnWwY4Tpc44h[XO|YYm= MX62NEBucW6| NYfKVJpXUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgWHlMOiCneIDy[ZN{\WRiaX6gRoEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25iYX\0[ZIhPjBibXnud{BjgSCDbIDoZXNkemWnbjDhd5NigSxiSVO1NEA:KDFwMjFOwG0v NHnNdXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC4O|c2OCd-MkKwPFc4PTB:L3G+
T-cells NFjkdGJHfW6ldHnvckBie3OjeR?= NHLMVJY4OiCqcoO= MXTJcohq[mm2aX;uJI9nKEqDS{OgbY4hemG2IIPwcIVvd2O7dHnjJHQh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFnMMVIucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFEvOiEQvF2u NVHWVnVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN|k2PzVpPkOwNVM6PTd3PD;hQi=>
SZ4 MnmzSpVv[3Srb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKEqDS{OgbY4hcHWvYX6gV3o1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDJUFIue3SrbYXsZZRm\CCVVFHUOUBxcG:|cHjvdplt[XSrb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IFnMNkB{fGmvdXzheIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiMUWgcYlveyCkeTDNV2Qh[XO|YYmsJGlEPTBiPTCxMlIyKM7:TT6= M4LNSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNE[wPFQzLz5|MES2NFg1OjxxYU6=
BAF3 MlTqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M4XHdFczKGi{cx?= NYPTVXhnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXEWOLVrBT|Ihc2mwYYPlJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEGuOVc1KM7:TT6= M3jOO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{[yNlM5Lz5zOUe2NlI{QDxxYU6=
HEL NXvYeG1kTnWwY4Tpc44h[XO|YYm= NVnOfJRKOSCqch?= NV\SOngxUW6qaXLpeIlwdiCxZjDKRWszKFZ4MUfGJI12fGGwdDDpckBpfW2jbjDISWwh[2WubIOgZYZ1\XJiMTDodkwhUUN3MDC9JFQvPzJ2IN88UU4> MnjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{GxPFAoRjJ5N{exNVgxRC:jPh?=
Jurkat M3rLfmZ2dmO2aX;uJIF{e2G7 NUX3NFliOjRiaILz MXzJcohq[mm2aX;uJI9nKGGwdHmtR2Q{N2GwdHmtR2QzQC2rbnT1Z4VlKEmOMjDwdo9lfWO2aX;uJIlvKGi3bXHuJGp2emujdDDj[YxteyCjZoTldkAzPCCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IEeuPFQh|ryPLh?= NYX0V4xWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
YT NXi2cohXTnWwY4Tpc44h[XO|YYm= NGTYflc{OCCwZz;tcC=> NF3FWYpKdmirYnn0bY9vKG:oIFnMNk1qdmS3Y3XkJGpCUzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFmWIHPlcIx{KGG2IEOwJI5oN22uIHL5JIludXWwb3Lsc5R1cW6pIHHuZYx6e2m| NFHVZWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
YT MX3GeY5kfGmxbjDhd5NigQ>? MUezNEBv\y:vbB?= MYXJcohq[mm2aX;uJI9nKEmOMj3pcoR2[2WmIGPURXQ2SSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hYVRiY3XscJMh[XRiM{CgcocwdWxiYomgbY1ufW6xYnzveJRqdmdiYX7hcJl{cXN? NHPGT409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
YT MmLXSpVv[3Srb36gZZN{[Xl? NVGxO2xnOzBibnevcYw> NXjH[4E6UW6qaXLpeIlwdiCxZjDJUFIucW6mdXPl[EBUXEGWNVKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGnUJINmdGy|IHH0JFMxKG6pL33sJIJ6KGmvbYXuc4Jtd3S2aX7nJIFv[Wy7c3nz NXm0ZnhRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
NK-cells MXXJcY12dm:|dYDwdoV{e2m4ZTDhd5NigQ>? MoXQNUB1dyB3IH3nM4to MUK0JJdm\Wu| Mkj4TY1ufW6xc4XwdJJme3OrdnWgZYN1cX[rdImgbY4hdmGrdnWgZ5lvd22xbHf1d{Bud26tZYmgZZN{\XO|ZXSgZZMh\W[oZXP0JI9vKEOGMz3DSFE3MyCQSzDj[YxteyCjdDCxJJRwKDVibXevb4ctKHCxIH\vdkA1KHenZXvz M3;weFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
T-cells MWPGeY5kfGmxbjDhd5NigQ>? NHTLfWM2KHSxIEWwNEBvVQ>? MWGxJIhz MnLHTY5pcWKrdHnvckBw\iCLTEKtbY5lfWOnZDDTeIF1PSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hS0R2KzDUJINmdGy|IHH0JFUhfG9iNUCwJI5OKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91 NFLKWYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC1N|c2Pid-MUmwOVM4PTZ:L3G+
SUM149PT MnXZSpVv[3Srb36gZZN{[Xl? MX2zJJVO NYHCXJEzOTZiaILz NYXG[XlSUW6mdXP0bY9vKG:oIGDUVG43KGmwIHj1cYFvKFOXTUG0PXBVKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IEOgeW0h[W[2ZYKgNVYhcHK|IHL5JHdme3Sncn6gZoxwfHSrbnegZY5idHm|aYOgbY4heHKnc3XuZ4Uhd2ZicHXyeoFv[WSjdHW= NGW3fWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3PFEyOid-MkS5O|gyOTJ:L3G+
Hs578T MoOzSpVv[3Srb36gZZN{[Xl? M3O4dlMhfU1? MWGxOkBpenN? M4LT[mlv\HWldHnvckBw\iCSVGDOOkBqdiCqdX3hckBJezV5OGSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVVFHUN{BxcG:|cHjvdplt[XSrb36gZZQhOyC3TTDh[pRmeiBzNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBx\XK4YX7h[IF1\Q>? M2\lO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUe4NVEzLz5{NEm3PFEyOjxxYU6=
T-cells MkPHSpVv[3Srb36gZZN{[Xl? MmL2OVAhfG9iM{CwJI5O M33IdVEhcHJ? NI\oTFVKdmirYnn0bY9vKG:oIFrBT|EwUkGNMzDpckBpfW2jbjDDSFQheG:|aYTpeoUhXCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNPC2|dHnteYxifGWmIGPURXQ3KHCqb4PwbI9zgWyjdHnvckBifCB3MDD0c{A{ODBibl2gdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IFnMMVQhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCrbX31co9jdG:2IHHuZYx6e2m| MmHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUKwOlgoRjJ7OEWyNFY5RC:jPh?=
T-cells M1GxdGZ2dmO2aX;uJIF{e2G7 M1rqc|UxKHSxIEOwNEBvVQ>? NVfBTWxmOSCqch?= M1XqUGlvcGmkaYTpc44hd2ZiSlHLNU9LSUt|IHnuJIh2dWGwIFPEOEBxd3OrdHn2[UBVKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWwzNXO2aX31cIF1\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIF1KFS7cj22PVUhemW|aXT1[UBifCB3MDD0c{A{ODBibl2gdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IFnMMVIhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCrbX31co9jdG:2IHHuZYx6e2m| NV70U4tRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVIxPjhpPkK5PFUzODZ6PD;hQi=>
T-cells Ml3MSpVv[3Srb36gZZN{[Xl? MXu+N|AxKG6P M2Sw[|EhcHJ? NIrUTJVKdmirYnn0bY9vKG:oIFrBT|EwUkGNMj;UXWszKGmwIHj1cYFvKEOGNDDwc5NqfGm4ZTDUJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiSVy2MZN1cW23bHH0[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHH0JF4{ODBibl2gdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IFnMMVYhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCrbX31co9jdG:2IHHuZYx6e2m| Mn;2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUKwOlgoRjJ7OEWyNFY5RC:jPh?=
TALL-1 Mo\iSpVv[3Srb36gZZN{[Xl? MUexJJVO M{C2W|MhcHK| NULvRXlNUW6qaXLpeIlwdiCxZjDKRWs{KGmwIHj1cYFvKFSDTFytNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMMVIhcW6mdXPl[EBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KEmOLUKgbY5lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgbY1ufW6xYnzveJRqdmd? NVvUNlQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
BA/F3 NHnj[YJHfW6ldHnvckBie3OjeR?= MlnmN|AxKG6P MUizJIhzew>? NFLteJNKdmirYnn0bY9vKG:oIFrBT|MhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDheEA{ODBibl2gZYZ1\XJiMzDodpMh[nliaX3teY5w[myxdITpcoch[W6jbInzbZM> NXrnSmh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
OCL-AML5 MYDGeY5kfGmxbjDhd5NigQ>? Mo\ENUB2VQ>? M32ze|MhcHK| M1jzOmlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBQS0xvQV3MOUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFfNMWNUTiCrbnT1Z4VlKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDheEAyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiMzDodpMh\m:ubH;3[YQh[nliR12tR3NHKGmwZIXjeIlwdiCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIJ6KGmvbYXuc4Jtd3S2aX7n MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
BA/F3 M1m0R2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M4X6b|czKGi{cx?= NGex[FdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochXEWOLVrBT|Mh[W[2ZYKgO|IhcHK|IHL5JINmdGxidHn0[ZIh\2yxIHHzd4F6 NWDzXXFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
BA/F3 NXHXdWZETnWwY4Tpc44h[XO|YYm= M4XUblEhfU1? MnXSN{BpenN? NUL4SmdLUW6qaXLpeIlwdiCxZjDKRWs{KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy|IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB|IHjyd{Bnd2yub4fl[EBjgSCydXzs[I94diC5aYToJJN1emWydHH2bYRqdiCkZXHkd{BjgSCrbX31co9jdG:2dHnu[{BidmGueYPpdy=> NYf2Z3k2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
Huh7 Mki2SpVv[3Srb36gZZN{[Xl? Ml7WNVAhfU1? NWnHWZFVOzBibXnudy=> MUXJcohq[mm2aX;uJI9nKFS7a{KgbY4hcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gTWZP[WyyaHG1MYlv\HWlZXSgV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKHC{ZT3pcoN2[mG2ZXSg[o9zKDNyIH3pcpMh[mWob4LlJGlHVmGucHjhOUB{fGmvdXzheIlwdiCob4KgN|AhdWmwczDtbY5{KGK7IHntcZVvd2Kub4T0bY5o M3jONVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkOxNVU6Lz5{NkKzNVE2QTxxYU6=
Huh7 NXnsZppJTnWwY4Tpc44h[XO|YYm= M{nZWFExKHWP NYLkNJhyOzBibXnudy=> NYLiTWhzUW6qaXLpeIlwdiCxZjDUfYszKGmwIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKGKjc3HsJIxmfmWuIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCBzMDD1UUBi\nSncjCzNEBucW6|IHL5JIludXWwb3Lsc5R1cW6p Mn3MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{GxOVkoRjJ4MkOxNVU6RC:jPh?=
Huh7 MX\GeY5kfGmxbjDhd5NigQ>? M2DPXlEhfU1? MlnSN|AhdWmwcx?= NWKx[md3UW6qaXLpeIlwdiCxZjDUfYszKGmwIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKEmITnHsdIhiPS2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEAyKHWPIIDy[U1qdmO3YnH0[YQh\m:{IEOwJI1qdnNiYnXmc5JmKEmITnHsdIhiPSC|dHnteYxifGmxbjDmc5IhOzBibXnud{BucW6|IHL5JIludXWwb3Lsc5R1cW6p NW\Bc5BSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN|EyPTlpPkK2NlMyOTV7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
JAK3 / STAT5 / p-STAT5 ; 

PubMed: 27732937     


The following cell lines: EBV-negative B cell line (BJAB), EBV-transformed lymphoblastoid cell line (LCL), EBV-negative T cell lines (Jurkat and MOLT4), EBV-positive T cell lines (SNT15 and SNT16), EBV-negative NK cell line (KHYG1), and EBV-positive NK cell lines (KAI3 and SNK6), were treated without (−) or with (+) 1 μM tofacitinib for 24 h and cell lysates were then immunoblotted for the indicated proteins.

LMP1 / EBNA1 / BZLF1 ; 

PubMed: 27732937     


SNT13, SNT15, SNT16, KAI3 and SNK6 cell lines were treated with 5 μM tofacitinib for 48 h, and cell lysates were immunoblotted for LMP1, EBNA1 and BZLF1. Actin was blotted as a loading control.

JAK3 / p-JAK3 / STAT3 ; 

PubMed: 26082451     


CTCL cell lines were subjected to western blot (tofacitinib 10, 100, 200 nM) (G) after 48 hours of treatment.

27732937 26082451
Growth inhibition assay
Cell number ; 

PubMed: 27732937     


BJAB, LCL, Jurkat, SNT15, KHYG1 and KAI3 cells were treated with the indicated concentrations of tofacitinib, and viable cells were counted at the indicated times using the trypan blue exclusion test. Values are means ± SE of the results from triplicate experiments. *P < 0.05 as compared with DMSO-treated cells.

27732937
In vivo In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be ~60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively). [1] Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrates dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87–30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice is observed with CP-690550 monotherapy (10–30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day). [2]

Protocol

Kinase Assay:

[1]

- Collapse

JAK3 Kinase Assay:

A fragment encoding the catalytic domain of human JAK3 (785aa to 1125aa, JH1 catalytic domain) is amplified by PCR from the full length cDNA and cloned into the EcoRI site of the baculovirus transfer vector pVL1393. Recombinant baculovirus is used to infect Sf9 (Spodoptera frugipedra) cells and recombinant GSTJAK3 fusion protein is isolated on glutathione sepharose. The fusion protein is eluted with reduced glutathione and stored in buffer containing 50 mM Tris, pH 7.5, 10 mM DTT and 10% glycerol. JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1) (100 ug/mL). The plates are washed and recombinant JAK3 JH1:GST (100 ng/well) with or without inhibitors is incubated at room temperature for 30 minutes, after which HRP-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3',5,5'-tetramethylbenzidine). Other kinases (Table 1) are produced in E. coli or in insect cells, depending upon what is found to be optimal for the given kinase. The catalytic activity of tyrosine kinases is easured using the aftorementioned ELISA, whereas serine/threonine kinases are assayed using radioactive enzyme assays.
Cell Research:

[1]

- Collapse
  • Cell lines: Human T blasts cell
  • Concentrations: 0-4000 nM
  • Incubation Time: 4 days
  • Method:

    To measure IL-2-dependent proliferation, isolated lymphocytes are resuspended to a cell density of 1-2 × 106/mL in complete RPMI medium (RPMI 1640 containing 10% (w/v) fetal calf serum (FCS), 1%(w/v) penicillin and treptomycin).Phytohemagluttinin (PHA) is added to a final concentration of 10mg/mL, and the culture incubated for 3 days at 37 °C in a humidified 5% (v/v) CO2 incubator to upregulate IL-2R and JAK3 expression. IL-2 (200U/mL), with or without CP-690,550 is then added and the cells are incubated for 72 hours at 37 °C in a humidified 5% (v/v) CO2 incubator, after which 50 mL of 3H-thymidine (5mCi/mL) is added. The plates are incubated for an additional 18 hours, harvested with a 96-well harvester, and counted on a scintillation counter. HUO3 cells are maintained in culture with granulocyte-macrophage colony stimulating factor and human foreskin fibroblasts are maintained in culture with 10% fetal calf serum. CP-690550 is added to freshly plated cells and cultured for 4 days. 3Hthymidine is added during the last 18 hours of the culture period.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: DBA/2 and C57/BL6 mice
  • Dosages: 0-136 ng/mL
  • Administration: Administered via osmotic minipump infusion
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 62 mg/mL warmed (198.48 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 312.37
Formula

C16H20N6O

CAS No. 477600-75-2
Storage powder
in solvent
Synonyms Tasocitinib
Smiles CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04624230 Recruiting Drug: tofacitinib Ulcerative Colitis Pfizer August 12 2021 Phase 3
NCT04496960 Recruiting Drug: tofacitinib|Other: Placebo Sjogren''s Syndrome National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) May 18 2021 Phase 1|Phase 2
NCT04768504 Not yet recruiting Drug: Tofacitinib 10 mg Immune-Mediated Colitis Khashayar Esfahani|Sir Mortimer B. Davis - Jewish General Hospital April 2021 Phase 2
NCT04424303 Recruiting Drug: Tofacitinib Ulcerative Colitis Pfizer December 7 2020 --
NCT04468425 Recruiting Drug: Tofacitinib Citrate Healthy Subjects TWi Biotechnology Inc. October 14 2020 Phase 1
NCT04338204 Recruiting Drug: tofacitinib Ulcerative Colitis Pfizer September 14 2020 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was just wondering what the main differences between S2789 and S5001?

  • Answer:

    S2789(Tofacitinib (CP-690550)) is the base form of S5001 (Tofacitinib (CP-690550) Citrate). The biological activity of these two compounds are same. The S5001 (Tofacitinib (CP-690550) Citrate) is more suitable for oral administration.

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

Related JAK Products

Tags: buy Tofacitinib (CP-690550) | Tofacitinib (CP-690550) supplier | purchase Tofacitinib (CP-690550) | Tofacitinib (CP-690550) cost | Tofacitinib (CP-690550) manufacturer | order Tofacitinib (CP-690550) | Tofacitinib (CP-690550) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID